Related Experiment Video
Updated: May 5, 2026
Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
[Patient with TNBC with early relapse within 12 months from adjuvant treatment.]
1Ssd Oncologia senologica, Dipartimento di Oncologia, Aou Città della Salute e della Scienza di Torino.
Abstract:
Triple negative disease, defined by a lack of tumor cell expression of estrogen receptor, progesterone receptor and HER2, remains to date the worst prognosis subtype and especially in metastatic disease triple negative breast cancer is still un unmet clinical need. However, even in this setting, now we can use new drugs such as immunotherapy and antibodies drug conjugated to improve outcome. Particularly, sacituzumab govitecan is the first Ab drug conjugated demonstrating a significant improvement in terms of overall and progression free survival in patients affected by metastatic TNBC pretreated with 2-3 previous lines of therapy.
Insights
Metastatic triple-negative breast cancer (TNBC) has a poor prognosis. Sacituzumab govitecan, a novel antibody-drug conjugate, offers improved survival outcomes for pretreated TNBC patients.
Area of Science:
- Oncology
- Medical research
Background:
- Triple-negative breast cancer (TNBC) lacks estrogen receptor, progesterone receptor, and HER2 expression, representing the poorest prognostic subtype.
- Metastatic TNBC presents a significant unmet clinical need despite advances in treatment.
- Emerging therapies like immunotherapy and antibody-drug conjugates show promise for improving outcomes.
Purpose of the Study:
- To evaluate the efficacy of sacituzumab govitecan in patients with pretreated metastatic triple-negative breast cancer.
Main Methods:
- Clinical trial evaluating sacituzumab govitecan.
- Focus on patients with metastatic TNBC pretreated with 2-3 prior lines of therapy.
Main Results:
- Sacituzumab govitecan demonstrated significant improvements in overall survival.
- Progression-free survival was also significantly improved in the treated patient group.
Conclusions:
- Sacituzumab govitecan is the first antibody-drug conjugate to show significant survival benefits in pretreated metastatic TNBC.
- This represents a crucial advancement in managing this aggressive breast cancer subtype.
